Second Sight Medical Products, Inc. (EYES)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Second Sight Medical Products, Inc. (EYES) with AI Score 43/100 (Grade C). Second Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics. As of August 30, 2022, Second Sight Medical Products, Inc. Sector: Healthcare.
Last analyzed: Mar 16, 2026EYES: the 1 perspectives are evenly split.
Second Sight Medical Products, Inc. (EYES) Healthcare & Pipeline Overview
Second Sight Medical Products, acquired by Nano Precision Medical, focuses on developing and marketing implantable visual prosthetics for blind individuals. Their primary product is the Orion Visual Cortical Prosthesis System, targeting vision loss due to conditions like glaucoma and diabetic retinopathy. The company operates within the medical devices industry.
What Is the Investment Thesis for EYES?
Second Sight Medical Products, Inc. presents a high-risk, high-reward investment profile, primarily due to its focus on innovative but unproven technology in the visual prosthetics field. The company's success hinges on the clinical efficacy and market acceptance of the Orion Visual Cortical Prosthesis System. With a market capitalization of $0.21 billion and a negative P/E ratio of -0.32, the company's valuation is speculative, reflecting the potential of its technology rather than current profitability. A gross margin of 50.0% indicates potential for profitability if sales volume increases. The company's high beta of 2.56 suggests significant volatility relative to the broader market. Key growth catalysts include successful clinical trials, regulatory approvals, and commercialization of the Orion system. The reverse merger with Nano Precision Medical, Inc. introduces additional uncertainty and potential synergies.
Based on FMP financials and quantitative analysis
EYES Key Highlights
- Market Cap: $0.21B indicates the company's size and market value.
- P/E Ratio: -0.32 reflects the company's current lack of profitability.
- Profit Margin: 15559645.8% suggests potential for high profitability if the company can scale its operations effectively.
- Gross Margin: 50.0% demonstrates the company's ability to generate revenue after accounting for the cost of goods sold.
- Beta: 2.56 indicates high volatility compared to the market.
Who Are EYES's Competitors?
Who Are EYES's Competitors?
EYES is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BSGM BioSig Technologies, Inc. | $6.10 | +37.08% | $191.13M | 61 |
| DCTH Delcath Systems, Inc. | $10.78 | -2.34% | $372.14M | 73 |
| SSII SS Innovations International, Inc. | $3.78 | -1.56% | 757M | 72 |
| PRCT PROCEPT BioRobotics Corporation | $27.83 | +3.07% | 2B | 70 |
| FORZ Forza Innovations Inc. | $0.00 | +0.00% | 253K | 69 |
| ATEC Alphatec Holdings, Inc. | $7.75 | -0.96% | $1.19B | 56 |
| APEN APEN | $9.99 | +0.71% | 580M | 56 |
| QTRX Quanterix Corporation | $3.30 | -1.12% | $155.45M | 56 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are EYES's Key Strengths?
- Proprietary Orion Visual Cortical Prosthesis System.
- Focus on addressing unmet needs in blindness.
- Experienced management team.
- Potential for high profit margins.
What Are EYES's Weaknesses?
- Limited commercial success to date.
- High research and development costs.
- Dependence on regulatory approvals.
- Small number of employees.
What Could Drive EYES Stock Higher?
- Regulatory approvals for the Orion Visual Cortical Prosthesis System in key markets.
- Clinical trial results demonstrating the safety and efficacy of the Orion system.
- Strategic partnerships with research institutions and hospitals.
- Technological advancements in visual prosthetics.
What Are the Key Risks for EYES?
- Competition from alternative therapies for blindness.
- Regulatory delays and uncertainties.
- Product liability claims.
- Limited commercial success and financial resources.
- Dependence on key personnel.
What Are the Growth Opportunities for EYES?
- Orion Visual Cortical Prosthesis System Commercialization: The successful commercialization of the Orion system represents a significant growth opportunity for Second Sight. This includes securing regulatory approvals, establishing manufacturing capabilities, and developing a robust sales and marketing strategy. The addressable market includes individuals blinded by glaucoma, diabetic retinopathy, optic nerve damage, and eye injury. This market is estimated to grow as the population ages and the prevalence of these conditions increases. Timeline: Ongoing, dependent on regulatory approvals and market adoption.
- Technological Advancements: Continuous improvement and innovation in visual prosthetic technology can drive growth. This includes enhancing the resolution, functionality, and user experience of the Orion system. Research and development efforts can focus on improving the biocompatibility of the implant, increasing the number of electrodes for finer visual perception, and developing more sophisticated image processing algorithms. Timeline: Ongoing, driven by research and development investments.
- Expansion of Indications: Expanding the indications for the Orion system to include other causes of blindness and visual impairment can broaden the addressable market. This requires conducting clinical trials to demonstrate the safety and efficacy of the system for new patient populations. Potential indications include macular degeneration, retinitis pigmentosa, and other inherited retinal diseases. Timeline: Dependent on clinical trial outcomes and regulatory approvals.
- Strategic Partnerships: Forming strategic partnerships with research institutions, hospitals, and other medical device companies can accelerate growth. These partnerships can provide access to new technologies, clinical expertise, and distribution channels. Collaboration with universities and research centers can facilitate the development of next-generation visual prosthetics. Timeline: Ongoing, dependent on identifying and securing suitable partnerships.
- Geographic Expansion: Expanding into new geographic markets can drive revenue growth. This requires obtaining regulatory approvals in each target market and establishing a local sales and marketing presence. Potential markets include Europe, Asia, and Latin America. Each market has its own regulatory requirements and competitive landscape. Timeline: Dependent on regulatory approvals and market entry strategies.
What Opportunities Does EYES Have?
- Expanding indications for the Orion system.
- Geographic expansion into new markets.
- Strategic partnerships with research institutions.
- Technological advancements in visual prosthetics.
What Threats Does EYES Face?
- Competition from alternative therapies.
- Regulatory hurdles and delays.
- Product liability risks.
- Economic downturn affecting healthcare spending.
What Are EYES's Competitive Advantages?
- Proprietary technology in visual prosthetics.
- Intellectual property protection through patents.
- First-mover advantage in the cortical stimulation field.
- Established relationships with key opinion leaders.
What Does EYES Do?
Second Sight Medical Products, Inc., founded in 1998 and headquartered in Sylmar, California, specializes in the development, manufacturing, and marketing of implantable visual prosthetics designed to restore a degree of artificial vision to blind individuals. The company's core technology centers around the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device. This system is intended to provide useful artificial vision to individuals who have lost their sight due to various conditions, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. The Orion system bypasses the damaged retina and optic nerve, directly stimulating the visual cortex of the brain. This approach aims to provide a form of artificial vision, enabling patients to perceive patterns of light and potentially navigate their environment more effectively. Second Sight's focus is on addressing the unmet needs of the sight-impaired population through innovative technological solutions. As of August 30, 2022, Second Sight Medical Products, Inc. was acquired by Nano Precision Medical, Inc., in a reverse merger transaction.
What Products and Services Does EYES Offer?
- Develops implantable visual prosthetics.
- Manufactures visual prosthetics devices.
- Markets visual prosthetics to treat blindness.
- Offers the Orion Visual Cortical Prosthesis System.
- Targets individuals blind due to glaucoma.
- Aims to help those with diabetic retinopathy.
- Provides solutions for optic nerve injury or disease.
- Addresses vision loss from eye injury.
How Does EYES Make Money?
- Develops and manufactures the Orion Visual Cortical Prosthesis System.
- Sells the Orion system to hospitals and clinics.
- Provides training and support to surgeons and patients.
- Generates revenue through the sale of implantable devices.
What Industry Does EYES Operate In?
Second Sight Medical Products operates within the medical devices industry, specifically focusing on visual prosthetics. This sector is characterized by technological innovation, high research and development costs, and stringent regulatory requirements. The market for visual prosthetics is relatively small but has the potential for significant growth as technology advances and the aging population increases. Competition includes companies developing alternative therapies for blindness and visual impairment. The industry is also influenced by advancements in neuroscience and neurotechnology.
Who Are EYES's Key Customers?
- Hospitals and clinics specializing in ophthalmology.
- Surgeons who perform retinal and cortical implants.
- Patients who are blind due to various causes.
- Research institutions conducting clinical trials.
EYES Financials
EYES Latest News
No recent news available for EYES.
EYES Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for EYES.
Price Targets
Wall Street price target analysis for EYES.
EYES MoonshotScore
What does this score mean?
The MoonshotScore rates EYES's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Matthew Pfeffer
CEO
Matthew Pfeffer serves as the CEO of Second Sight Medical Products, managing a team of 15 employees. His background includes extensive experience in the healthcare and medical device industries. Pfeffer's expertise spans strategic planning, financial management, and operational leadership. He has a proven track record of driving growth and innovation in the medical technology sector. His leadership is focused on advancing Second Sight's mission to restore vision to blind individuals through innovative prosthetic devices.
Track Record: Under Pfeffer's leadership, Second Sight has focused on refining its Orion Visual Cortical Prosthesis System and navigating the regulatory landscape. Key milestones include securing funding for clinical trials and pursuing regulatory approvals for the Orion system. Pfeffer has also overseen the company's strategic shift towards cortical stimulation technology. The acquisition by Nano Precision Medical, Inc. occurred during his tenure.
EYES Healthcare Stock FAQ
What does Second Sight Medical Products, Inc. do?
Second Sight Medical Products, Inc. focuses on developing, manufacturing, and marketing implantable visual prosthetics designed to restore a degree of artificial vision to individuals who are blind. Their primary product is the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device intended to provide useful artificial vision to individuals who have lost their sight due to conditions such as glaucoma, diabetic retinopathy, optic nerve injury, or disease. The company was acquired by Nano Precision Medical, Inc. in a reverse merger transaction.
What do analysts say about EYES stock?
AI analysis is pending for EYES stock. However, based on available financial data, Second Sight Medical Products, Inc. has a market capitalization of $0.21 billion and a negative P/E ratio of -0.32, indicating that the company is not currently profitable. The company's high profit margin of 15559645.8% and gross margin of 50.0% suggest potential for profitability if the company can scale its operations effectively. The stock's high beta of 2.56 indicates significant volatility compared to the broader market.
What are the main risks for EYES?
The main risks for Second Sight Medical Products, Inc. include the limited commercial success to date, high research and development costs, dependence on regulatory approvals, and competition from alternative therapies for blindness. The company's financial resources are limited, and its success depends on the clinical efficacy and market acceptance of the Orion Visual Cortical Prosthesis System. Product liability claims and regulatory delays also pose significant risks.
What are the key factors to evaluate for EYES?
Second Sight Medical Products, Inc. (EYES) currently holds an AI score of 43/100, indicating low score. Key strength: Proprietary Orion Visual Cortical Prosthesis System. Primary risk to monitor: Competition from alternative therapies for blindness. This is not financial advice.
How frequently does EYES data refresh on this page?
EYES prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven EYES's recent stock price performance?
Recent price movement in Second Sight Medical Products, Inc. (EYES) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary Orion Visual Cortical Prosthesis System. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider EYES overvalued or undervalued right now?
Determining whether Second Sight Medical Products, Inc. (EYES) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying EYES?
Before investing in Second Sight Medical Products, Inc. (EYES), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-03-16.
- AI analysis is pending for EYES stock.
- The company was acquired by Nano Precision Medical, Inc. in a reverse merger transaction.